Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi's Forecast for HENGRUI PHARMA's Results Over Next 3 Yrs (Table)
Recommend 12 Positive 16 Negative 11 |
||||
|
||||
|
HENGRUI PHARMA (01276.HK), known as the “Moutai as Medicine”, a major pharmaceutical company in Mainland China, debuted in Hong Kong today with an opening price of HKD57, which was 29.4% above its listing price of HKD44.05. The stock touched an intraday high of HKD60.6 and settled at HKD57.65 midday, up 30.9% from its listing price, with a turnover of HKD3.919 billion. Hengrui A-shares (600276.SH) closed at RMB55.36 midday, down narrowly by 0.07%. In early May, Citi had published a report projecting Hengrui’s revenue CAGR from 2024 to 2027 at 21%, with total pharmaceutical sales CAGR at 22%, and innovative drug business revenue CAGR at 35%. The broker also outlined its results forecasts for Hengrui over the next three years: Items│2025 Forecast│2026 Forecast│2027 Forecast Revenue │ 35.493 billion │ 41.937 billion │ 49.327 billion Gross profit │ 30.588 billion │ 36.353 billion │ 42.997 billion Operating profit │ 10.344 billion │ 12.612 billion │ 14.93 billion EBIT │ 9.936 billion │ 12.131 billion │ 14.365 billion Net profit │8.777 billion │10.677 billion │12.651 billion Gross profit margin │86.2%│86.7%│87.2% Net profit margin │24.7%│25.5%│25.6% The above currencies are all in RMB AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
